Bank Of New York Mellon Corp Kymera Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $19.4 Million - $30.6 Million	989,966 New	989,966 $24.7 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $12,169 - $19,945	582 Added 0.06%	1,025,244 $22.3 Million
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $4.78 Million - $14.4 Million	338,468 Added 49.33%	1,024,662 $20.2 Million
Q1 2022 May 11, 2022	BUY	$35.3 - $64.68 $5.49 Million - $10.1 Million	155,476 Added 29.3%	686,194 $29 Million
Q4 2021 Feb 11, 2022	BUY	$49.91 - $65.56 $1.49 Million - $1.96 Million	29,838 Added 5.96%	530,718 $33.7 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $20.7 Million - $28.8 Million	432,300 Added 630.36%	500,880 $29.4 Million
Q2 2021 Aug 11, 2021	BUY	$31.08 - $51.95 $939,983 - $1.57 Million	30,244 Added 78.89%	68,580 $3.33 Million
Q1 2021 May 13, 2021	SELL	$35.64 - $85.46 $68,571 - $164,425	-1,924 Reduced 4.78%	38,336 $1.49 Million
Q4 2020 Feb 09, 2021	BUY	$28.07 - $87.83 $1.13 Million - $3.54 Million	40,260 New	40,260 $2.5 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.28B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.